Moderna’s CFO Leaves After Just One Day On The Job — And Withdraws His Entire First Year Salary

Talk about a quick run after securing the money!

Maddie Meyer/Getty Images

Maddie Meyer/Getty Images

On Wednesday, pharmaceutical company Moderna announced that its CFO Jorge Gomez left after just one day on the job — but he will still receive his full 12-month salary.

Prior to accepting his role at Moderna, Gomez served as Executive Vice President and Chief Financial Officer of Dentsply Sirona Inc. since August 2019.

“The announcement follows the May 10 public disclosure by Gomez’s former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting,” Moderna said in a company statement.

The internal investigation in question will determine whether the incentives that were used to help sell the dental supplier’s products to major distributors were “properly accounted for,” according to CNBC.

Gomez’s departure takes effect immediately, with the company’s recently retired former CFO David Meline filling the role during the interim hiring process for a new candidate.

Related: Moderna shares soar after company says its Covid Booster increases antibody levels against Omicron

Gomez was announced as Moderna’s new CFO on April 11, with the position taking effect on May 9.

“It is a privilege for me to join an organization focused on developing transformative medicines to address major public health challenges around the world,” Gomez said at the time. “I look forward to working with the team on this great mission.”

Gomez’ will still receive his $700,000 salary, although he will no longer be eligible for his signing bonus or future bonuses within the one-year period.

Denstsply board member and former Hillrom CEO John Groetelaars is currently serving as interim CEO.

The news comes after the April 19 announcement that Dentsply CEO Don Casey was fired from his position at the company after four years, three weeks before the company announced its less-than-stellar Q1 2022 earnings.

“The first quarter was challenging, and our revised financial performance and outlook reflect the impact of stronger-than-expected macroeconomic winds and lower-than-expected performance in the United States,” Interim CEO Groetelaars told shareholders.

Moderna, on the other hand, had an exceptional first quarter, tripling sales of Covid vaccines to an estimated revenue of $5.9 billion, which sent the stock soaring more than 7% in pre-sales trading. Wednesday market.

Related: Moderna says its vaccine is 96% effective in teens

Leave a Reply

Your email address will not be published.